Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Study of SHR6390 in Renal Insufficiency and Healthy Subjects
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05515289
- Locations
- 🇨🇳
Zhongda Hospital Southesat University, Nanjing, Jiangsu, China
Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 129
- Registration Number
- NCT05513976
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 324
- Registration Number
- NCT05482568
- Locations
- 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT05476900
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine, Renji Hospital, Shanghai, Shanghai, China
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 153
- Registration Number
- NCT05473624
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳The First Hospital of China Medical University, Shenyang, Liaoning, China
Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05473468
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of HR18042 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery.
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT05470075
- Locations
- 🇨🇳
West China Hospital of Stomatology Sichuan University, Chengdu, Sichuan, China
A Clinical Study of the Combination of SHR8554 Injection and SHR0410 Injection for the Treatment of Pain After Abdominal Surgery.
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05470049
A Trial of SHR0410 Injection for the Treatment of Pain After Laparoscopic Surgery
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 357
- Registration Number
- NCT05459220
A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 357
- Registration Number
- NCT05442827
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
© Copyright 2024. All Rights Reserved by MedPath